Search

Your search keyword '"Musca, Tania"' showing total 9 results
Start Over Author "Musca, Tania"
9 results on '"Musca, Tania"'

2. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial

Author

Shabat, C. S., Scaldaferri, Franco, Zittan, E., Hirsch, A., Mentella, Maria Chiara, Musca, Tania, Cohen, N. A., Ron, Y., Isakov, N. F., Pfeffer, J., Yaakov, M., Fanali, Chiara, Turchini, Laura, Masucci, Luca, Quaranta, Gianluca, Kolonimos, N., Godneva, A., Weinberger, A., Kopylov, U., Levine, A., Maharshak, N., Scaldaferri F. (ORCID:0000-0001-8334-7541), Mentella M. C. (ORCID:0000-0003-4552-3932), Musca T., Fanali C., Turchini L., Masucci L. (ORCID:0000-0002-8358-6726), Quaranta G., Shabat, C. S., Scaldaferri, Franco, Zittan, E., Hirsch, A., Mentella, Maria Chiara, Musca, Tania, Cohen, N. A., Ron, Y., Isakov, N. F., Pfeffer, J., Yaakov, M., Fanali, Chiara, Turchini, Laura, Masucci, Luca, Quaranta, Gianluca, Kolonimos, N., Godneva, A., Weinberger, A., Kopylov, U., Levine, A., Maharshak, N., Scaldaferri F. (ORCID:0000-0001-8334-7541), Mentella M. C. (ORCID:0000-0003-4552-3932), Musca T., Fanali C., Turchini L., Masucci L. (ORCID:0000-0002-8358-6726), and Quaranta G.

Abstract

Background: We evaluated whether integration of novel diets for donors and patients, in addition to faecal transplantation [FT], could increase FT remission rate in refractory ulcerative colitis [UC]. Methods: This was a blinded, randomised, controlled trial in adults with active UC, defined by a simple clinical colitis activity index [SCCAI] of ≥5 and ≤11 and endoscopic Mayo score 2-3, refractory to medication. Group 1 received free diet and single donor standard FT by colonoscopy on Day 1and rectal enemas on Days 2 and 14 without dietary conditioning of the donor. Group 2 received FT as above but with dietary pre-conditioning of the donor for 14 days and a UC Exclusion Diet [UCED] for the patients. Group 3 received the UCED alone. The primary endpoint was Week 8 clinical steroid-free remission, defined as SCCAI <3. Results: Of 96 planned patients, 62 were enrolled. Remission Week 8 Group 1 was 2/17 [11.8%], Group 2 was 4/19 [21.1%], Group 3 was 6/15 [40%] [non-significant]. Endoscopic remission Group 1 was 2/17 [12%], Group 2 was 3/19 [16%], Group 3 was 4/15 [27%] [Group 1 vs 3 p = 0.38]. Mucosal healing [Mayo 0] was achieved only in Group 3 [3/15, 20%] vs 0/36 FT patients [p = 0.022]. Exacerbation of disease occurred in 3/17 [17.6%] of Group 1, 4/19 [21.1%] of Group 2, and 1/15 [6.7%] of Group 3 [Group 2 vs 3, p = 0.35]. Conclusions: UCED alone appeared to achieve higher clinical remission and mucosal healing than single donor FT with or without diet. The study was stopped for futility by a safety monitoring board.

Published
2022

3. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial

Author

Sarbagili Shabat, Chen, primary, Scaldaferri, Franco, additional, Zittan, Eran, additional, Hirsch, Ayal, additional, Mentella, Maria Chiara, additional, Musca, Tania, additional, Cohen, Nathaniel Aviv, additional, Ron, Yulia, additional, Fliss Isakov, Naomi, additional, Pfeffer, Jorge, additional, Yaakov, Michal, additional, Fanali, Caterina, additional, Turchini, Laura, additional, Masucci, Luca, additional, Quaranta, Gianluca, additional, Kolonimos, Nitzan, additional, Godneva, Anastasia, additional, Weinberger, Adina, additional, Kopylov, Uri, additional, Levine, Arie, additional, and Maharshak, Nitsan, additional

Published
2021
Full Text
View/download PDF

4. Diet Intervention Study through Telemedicine Assistance for Systemic Nickel Allergy Syndrome Patients during the COVID-19 Pandemic

Author

Nucera, Eleonora, primary, Rizzi, Angela, additional, Chini, Raffaella, additional, Giangrossi, Sara, additional, Lohmeyer, Franziska Michaela, additional, Parrinello, Giuseppe, additional, Musca, Tania, additional, Miggiano, Giacinto Abele Donato, additional, Gasbarrini, Antonio, additional, and Inchingolo, Riccardo, additional

Published
2021
Full Text
View/download PDF

5. Diet intervention study through telemedicine assistance for systemic nickel allergy syndrome patients during the covid-19 pandemic

Author

Nucera, Eleonora, Rizzi, Angela, Chini, R., Giangrossi, S., Lohmeyer, F. M., Parrinello, Giuseppe, Musca, Tania, Miggiano, Giacinto Abele Donato, Gasbarrini, Antonio, Inchingolo, Riccardo, Nucera E. (ORCID:0000-0002-0565-7680), Rizzi A. (ORCID:0000-0002-6795-746X), Parrinello G., Musca T., Miggiano G. A. D. (ORCID:0000-0002-8627-5528), Gasbarrini A. (ORCID:0000-0002-7278-4823), Inchingolo R. (ORCID:0000-0003-2843-9966), Nucera, Eleonora, Rizzi, Angela, Chini, R., Giangrossi, S., Lohmeyer, F. M., Parrinello, Giuseppe, Musca, Tania, Miggiano, Giacinto Abele Donato, Gasbarrini, Antonio, Inchingolo, Riccardo, Nucera E. (ORCID:0000-0002-0565-7680), Rizzi A. (ORCID:0000-0002-6795-746X), Parrinello G., Musca T., Miggiano G. A. D. (ORCID:0000-0002-8627-5528), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Inchingolo R. (ORCID:0000-0003-2843-9966)

Abstract

Background: Restrictions due to the COVID-19 pandemic limited patients’ access to hospital care. The aims of this study were to assess dietary nutritional status, quality of life (QoL), and adherence to dietary therapy before and after 30-day personalized diet therapy through telenutrition tools in patients with systemic nickel allergic syndrome (SNAS). Methods: Each SNAS patient underwent the following allergological procedures: (a) face-to-face visit (nutritional visit and QoL evaluation) with prescription of one out of five personalized and balanced dietary plans different for calorie intake, (b) video call visit for dietary evaluation and assessment of adherence to diet after 15 days, and (c) video call visit for dietary and QoL evaluation and assessment of adherence to diet therapy after 30 days (end of study). Results: We enrolled 20 SNAS patients. After 15 and 30 days, we found a statistically significant improvement in anthropometric findings after diet therapy, a significant adherence rate to low-nickel diet (60% and 80%, respectively), and an improvement in QoL with an increase in almost all psychometric indices. Conclusions: Our study demonstrates that telenutrition can be a valid tool to monitor nutritional status and adherence to balanced low-Ni diet positively affecting QoL in SNAS patients during the COVID-19 pandemic.

Published
2021

6. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial.

Author

Shabat, Chen Sarbagili, Scaldaferri, Franco, Zittan, Eran, Hirsch, Ayal, Mentella, Maria Chiara, Musca, Tania, Cohen, Nathaniel Aviv, Ron, Yulia, Isakov, Naomi Fliss, Pfeffer, Jorge, Yaakov, Michal, Fanali, Caterina, Turchini, Laura, Masucci, Luca, Quaranta, Gianluca, Kolonimos, Nitzan, Godneva, Anastasia, Weinberger, Adina, Kopylov, Uri, and Levine, Arie

Abstract

Background We evaluated whether integration of novel diets for donors and patients, in addition to faecal transplantation [FT], could increase FT remission rate in refractory ulcerative colitis [UC]. Methods This was a blinded, randomised, controlled trial in adults with active UC, defined by a simple clinical colitis activity index [SCCAI] of ≥5 and ≤11 and endoscopic Mayo score 2–3, refractory to medication. Group 1 received free diet and single donor standard FT by colonoscopy on Day 1and rectal enemas on Days 2 and 14 without dietary conditioning of the donor. Group 2 received FT as above but with dietary pre-conditioning of the donor for 14 days and a UC Exclusion Diet [UCED] for the patients. Group 3 received the UCED alone. The primary endpoint was Week 8 clinical steroid-free remission, defined as SCCAI <3. Results Of 96 planned patients, 62 were enrolled. Remission Week 8 Group 1 was 2/17 [11.8%], Group 2 was 4/19 [21.1%], Group 3 was 6/15 [40%] [non-significant]. Endoscopic remission Group 1 was 2/17 [12%], Group 2 was 3/19 [16%], Group 3 was 4/15 [27%] [Group 1 vs 3 p  = 0.38]. Mucosal healing [Mayo 0] was achieved only in Group 3 [3/15, 20%] vs 0/36 FT patients [ p  = 0.022]. Exacerbation of disease occurred in 3/17 [17.6%] of Group 1, 4/19 [21.1%] of Group 2, and 1/15 [6.7%] of Group 3 [Group 2 vs 3, p  = 0.35]. Conclusions UCED alone appeared to achieve higher clinical remission and mucosal healing than single donor FT with or without diet. The study was stopped for futility by a safety monitoring board. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide

Author

Scaldaferri, Franco, Pizzoferrato, Marco, Lopetuso, Loris Riccardo, Musca, Tania, Ingravalle, Maria Floriana, Sicignano, Ludovico Luca, Mentella, Maria Chiara, Miggiano, Giacinto Abele Donato, Mele, Maria Cristina, Gaetani, Eleonora, Graziani, Cristina, Petito, Valentina, Cammarota, Giovanni, Marzetti, Emanuele, Martone, A., Landi, Francesco, Gasbarrini, Antonio, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Mentella, Maria Chiara (ORCID:0000-0003-4552-3932), Miggiano, Giacinto Abele Donato (ORCID:0000-0002-8627-5528), Mele, Maria Cristina (ORCID:0000-0003-0153-5819), Gaetani, Eleonora (ORCID:0000-0002-7808-1491), Cammarota, Giovanni (ORCID:0000-0002-3626-6148), Marzetti, Emanuele (ORCID:0000-0001-9567-6983), Landi, Francesco (ORCID:0000-0002-3472-1389), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Scaldaferri, Franco, Pizzoferrato, Marco, Lopetuso, Loris Riccardo, Musca, Tania, Ingravalle, Maria Floriana, Sicignano, Ludovico Luca, Mentella, Maria Chiara, Miggiano, Giacinto Abele Donato, Mele, Maria Cristina, Gaetani, Eleonora, Graziani, Cristina, Petito, Valentina, Cammarota, Giovanni, Marzetti, Emanuele, Martone, A., Landi, Francesco, Gasbarrini, Antonio, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Mentella, Maria Chiara (ORCID:0000-0003-4552-3932), Miggiano, Giacinto Abele Donato (ORCID:0000-0002-8627-5528), Mele, Maria Cristina (ORCID:0000-0003-0153-5819), Gaetani, Eleonora (ORCID:0000-0002-7808-1491), Cammarota, Giovanni (ORCID:0000-0002-3626-6148), Marzetti, Emanuele (ORCID:0000-0001-9567-6983), Landi, Francesco (ORCID:0000-0002-3472-1389), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Malnutrition is a major complication of inflammatory bowel disease (IBD). This mini review is focusing on main determinants of malnutrition in IBD, the most important components of malnutrition, including lean mass loss and sarcopenia, as an emerging problem. Each one of these components needs to be well considered in a correct nutritional evaluation of an IBD patient in order to build a correct multidisciplinary approach. The review is then focusing on possible instrumental and clinical armamentarium for the nutritional evaluation.

Published
2017

9. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial.

Author

Sarbagili Shabat C, Scaldaferri F, Zittan E, Hirsch A, Mentella MC, Musca T, Cohen NA, Ron Y, Fliss Isakov N, Pfeffer J, Yaakov M, Fanali C, Turchini L, Masucci L, Quaranta G, Kolonimos N, Godneva A, Weinberger A, Kopylov U, Levine A, and Maharshak N

Subjects
Adult, Colonoscopy, Diet, Humans, Remission Induction, Colitis, Ulcerative drug therapy, Colitis, Ulcerative surgery, Fecal Microbiota Transplantation adverse effects
Abstract

Background: We evaluated whether integration of novel diets for donors and patients, in addition to faecal transplantation [FT], could increase FT remission rate in refractory ulcerative colitis [UC]., Methods: This was a blinded, randomised, controlled trial in adults with active UC, defined by a simple clinical colitis activity index [SCCAI] of ≥5 and ≤11 and endoscopic Mayo score 2-3, refractory to medication. Group 1 received free diet and single donor standard FT by colonoscopy on Day 1and rectal enemas on Days 2 and 14 without dietary conditioning of the donor. Group 2 received FT as above but with dietary pre-conditioning of the donor for 14 days and a UC Exclusion Diet [UCED] for the patients. Group 3 received the UCED alone. The primary endpoint was Week 8 clinical steroid-free remission, defined as SCCAI <3., Results: Of 96 planned patients, 62 were enrolled. Remission Week 8 Group 1 was 2/17 [11.8%], Group 2 was 4/19 [21.1%], Group 3 was 6/15 [40%] [non-significant]. Endoscopic remission Group 1 was 2/17 [12%], Group 2 was 3/19 [16%], Group 3 was 4/15 [27%] [Group 1 vs 3 p = 0.38]. Mucosal healing [Mayo 0] was achieved only in Group 3 [3/15, 20%] vs 0/36 FT patients [p = 0.022]. Exacerbation of disease occurred in 3/17 [17.6%] of Group 1, 4/19 [21.1%] of Group 2, and 1/15 [6.7%] of Group 3 [Group 2 vs 3, p = 0.35]., Conclusions: UCED alone appeared to achieve higher clinical remission and mucosal healing than single donor FT with or without diet. The study was stopped for futility by a safety monitoring board., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results